Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Facet seeks better offer after Biogen Idec's bid falls through

This article was originally published in Scrip

Executive Summary

Facet Biotech is looking for companies to acquire it on better terms than the $17.50 per share offer by Biogen Idec that fell through this week. President and CEO Faheem Hasnain added that Facet continued "to offer Biogen Idec the opportunity to engage in due diligence discussions to determine whether [the latter] would make a materially increased offer".



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts